<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00988052</url>
  </required_header>
  <id_info>
    <org_study_id>MS-LAQ-301E</org_study_id>
    <secondary_id>2009-012989-30</secondary_id>
    <nct_id>NCT00988052</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course</brief_title>
  <official_title>A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-301 (ALLEGRO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing MS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to make laquinimod 0.6 mg available for all subjects who
      completed the placebo-controlled MS-LAQ-301 study according to the protocol and to evaluate
      the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6
      mg in subjects with relapsing multiple sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the
    study drug in the relevant dose.
  </why_stopped>
  <start_date type="Actual">November 10, 2009</start_date>
  <completion_date type="Actual">July 1, 2017</completion_date>
  <primary_completion_date type="Actual">July 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Day 1 up to 7.64 years</time_frame>
    <description>A treatment-emergent adverse event was defined as any untoward medical occurrence that develops or worsens in severity following start of treatment and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. TEAEs associated with cancer, ischemic heart disease, cerebrovascular events, and arthritis were considered to be of special interest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Potentially Clinically Significant Abnormal Vital Signs</measure>
    <time_frame>Day 1 up to 7.64 years</time_frame>
    <description>Vital signs with potentially clinically significant abnormal results were evaluated using the following significance criteria:
Pulse rate low: &lt;=45 and decrease &gt;=30 beats/minute
Pulse rate high: &gt;=120 and increase &gt;=30 beats/minute
Systolic blood pressure low: &lt;=90 and decrease &gt;=30 mmHg
Systolic blood pressure high: &gt;=180 and increase &gt;=30 mmHg
Diastolic blood pressure low: &lt;=50 and decrease &gt;=20 mmHg
Diastolic blood pressure high: &gt;=100 and increase &gt;=20 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Serum Chemistry Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study</measure>
    <time_frame>Day 1 up to 7.64 years</time_frame>
    <description>Counts include two conditions:
a change from High / Non-PCS at baseline to Low PCS at any point during the study
a change from Low / Non-PCS at baseline to High PCS at any point during the study Participants whose condition was not changed from baseline or was changed to a non- PCS value are included in the population count. ALT=alanine aminotransferase ALP=alkaline phosphatase P-amylase=amylase, pancreatic AST=aspartate aminotransferase CRP=C reactive protein CK=creatine kinase CTN=creatinine FIB=fibrinogen GGT=gamma glutamyl transferase K=potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Serum Hematology Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study</measure>
    <time_frame>Day 1 up to 7.64 years</time_frame>
    <description>Counts include two conditions:
a change from High / Non-PCS at baseline to Low PCS at any point during the study
a change from Low / Non-PCS at baseline to High PCS at any point during the study Participants whose condition was not changed from baseline or was changed to a non- PCS value are included in the population count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Electrocardiogram (ECG) Fiindings That Shifted From Baseline to Any Time During the Study</measure>
    <time_frame>Day 1 up to 7.64 years</time_frame>
    <description>Shifts are presented as Baseline finding / Worse finding at anytime during the study.
Categories for findings are:
normal
abnormal, not clinically significant (Not CS)
abnormal, clinically significant (CS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">839</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Laquinimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One capsule containing 0.6 mg laquinimod to be administered orally once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Laquinimod</intervention_name>
    <description>One capsule containing 0.6 mg laquinimod to be administered orally once daily.</description>
    <arm_group_label>Laquinimod</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have completed the Termination visit of MS-LAQ-301 (completion of all
             Termination visit activities) according to the MS-LAQ-301 protocol.

          2. Women of child-bearing potential must practice an acceptable method of birth control
             [acceptable methods of birth control in this open label extension phase include:
             surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch
             (or hormone-releasing vaginal ring), long-acting injectable contraceptive, partner's
             vasectomy or double-barrier method (condom or diaphragm with spermicide)] during the
             study and up to 30 days after the last dose of the study drug..

          3. Subjects must be willing and able to comply with the protocol requirements for the
             duration of the study.

          4. Subjects must be able to comprehend, sign and date a written informed consent prior to
             entering the MS-LAQ-301E study.

        Exclusion Criteria:

          1. Premature discontinuation from the MS-LAQ-301 study, for any reason.

          2. Pregnancy [according to urine dipstick Î²-HCG test performed at Baseline (Month 0E)
             visit] or breastfeeding.

          3. Subjects with clinically significant or unstable medical or surgical condition
             detected or worsened during the MS-LAQ-301 study, which preclude safe participation
             and completion of the MS-LAQ-301E study. Acute exacerbation of MS will not exclude
             participation in the MS-LAQ-301E study.

          4. Use of inhibitors of CYP3A4 within 2 weeks prior to baseline visit (V0E, Month 0E).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giancarlo Comi, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U.O.Neurology-Neurorehabilitation and Clinical Neurophysiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 1076</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1090</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1088</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1102</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <zip>60062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1081</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1083</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1086</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1101</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1096</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1093</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1098</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1082</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1073</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1097</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1084</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1092</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1100</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1075</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1078</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1085</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3300</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3303</name>
      <address>
        <city>Linz</city>
        <zip>A-4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3302</name>
      <address>
        <city>St. Poelten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5901</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5904</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5903</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5900</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5905</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5902</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1132</name>
      <address>
        <city>Bedford</city>
        <state>Nova Scotia</state>
        <zip>B4A 1A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1126</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1128</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1134</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1130</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1129</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1131</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5417</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5416</name>
      <address>
        <city>Ostrava - poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5504</name>
      <address>
        <city>Tallinn</city>
        <zip>EE-10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5505</name>
      <address>
        <city>Tartu</city>
        <zip>EE-51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3525</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3527</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3526</name>
      <address>
        <city>Clermont-Ferrand Cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3524</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3528</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3529</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8100</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8101</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3247</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3241</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3238</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3248</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3245</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3237</name>
      <address>
        <city>Emden</city>
        <zip>26721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3242</name>
      <address>
        <city>Erbach</city>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3240</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3249</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3236</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3246</name>
      <address>
        <city>Hamburg</city>
        <zip>22417</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3239</name>
      <address>
        <city>Hannover</city>
        <zip>30171</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3243</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3251</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3250</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3244</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5115</name>
      <address>
        <city>Budapest</city>
        <zip>H-1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5114</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5116</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5117</name>
      <address>
        <city>Veszprem</city>
        <zip>H-8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8031</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8030</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8033</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262160</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8032</name>
      <address>
        <city>Tel Aviv</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3044</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3045</name>
      <address>
        <city>Fidenza</city>
        <zip>43036</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3042</name>
      <address>
        <city>Gallarate</city>
        <zip>21013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3046</name>
      <address>
        <city>Grosseto</city>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3038</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 555</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3039</name>
      <address>
        <city>Milano</city>
        <zip>20148</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3041</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3040</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5704</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5705</name>
      <address>
        <city>Siauliai</city>
        <zip>76231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3810</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3809</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5322</name>
      <address>
        <city>Czestochowa</city>
        <zip>42-280</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5320</name>
      <address>
        <city>Gorzow Wielkopolski</city>
        <zip>66-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5316</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5318</name>
      <address>
        <city>Kielce</city>
        <zip>25-726</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5319</name>
      <address>
        <city>Konskie</city>
        <zip>26-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5317</name>
      <address>
        <city>Krakow</city>
        <zip>31-826</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5315</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5325</name>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5208</name>
      <address>
        <city>Bucharest</city>
        <zip>011461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5210</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400437</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5212</name>
      <address>
        <city>Constanta</city>
        <zip>900123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5211</name>
      <address>
        <city>Targu-Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5209</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5029</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5021</name>
      <address>
        <city>Moscow</city>
        <zip>127015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5028</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5027</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5030</name>
      <address>
        <city>Perm</city>
        <zip>614990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5022</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5025</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5024</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5023</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5026</name>
      <address>
        <city>St.Petersburg</city>
        <zip>191186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6100</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6102</name>
      <address>
        <city>Nis</city>
        <zip>18 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3132</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3134</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3144</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3140</name>
      <address>
        <city>Beade-Pontevedra</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3142</name>
      <address>
        <city>Getafe</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3135</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3133</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3146</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3137</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3138</name>
      <address>
        <city>Pontevedra</city>
        <zip>36001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3136</name>
      <address>
        <city>Salt</city>
        <zip>17190</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3139</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3143</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 4204</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 4205</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 4206</name>
      <address>
        <city>Stockholm</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8201</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5803</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5802</name>
      <address>
        <city>Kyiv</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5804</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5800</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5801</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3425</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3424</name>
      <address>
        <city>London</city>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3422</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Latvia</country>
  </removed_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 28, 2009</study_first_submitted>
  <study_first_submitted_qc>September 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2009</study_first_posted>
  <results_first_submitted>November 28, 2018</results_first_submitted>
  <results_first_submitted_qc>January 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2019</results_first_posted>
  <last_update_submitted>January 7, 2019</last_update_submitted>
  <last_update_submitted_qc>January 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 25, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT00988052/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In the preceding double-blind, placebo-controlled ALLEGRO study (study MS-LAQ-301), 1106 subjects with RRMS were randomized to treatment, and 864 subjects completed the study according to the protocol (ie, by completing the ALLEGRO study termination visit procedures).</recruitment_details>
      <pre_assignment_details>In this open-label extension study, 839 subjects with RRMS were enrolled to receive laquinimod 0.6 mg at 135 study sites in 22 countries by 135 investigators.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Early Laquinimod</title>
          <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-301 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
        </group>
        <group group_id="P2">
          <title>Switch From Placebo</title>
          <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-301 double-blind study who were administered placebo daily for 24 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="423"/>
                <participants group_id="P2" count="416"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="423"/>
                <participants group_id="P2" count="416"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Teva requested subject withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="236"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants enrolled in the MS-LAQ-301 extension study.</population>
      <group_list>
        <group group_id="B1">
          <title>Early Laquinimod</title>
          <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-301 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
        </group>
        <group group_id="B2">
          <title>Switch From Placebo</title>
          <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-301 double-blind study who were administered placebo daily for 24 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="423"/>
            <count group_id="B2" value="416"/>
            <count group_id="B3" value="839"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="9.10"/>
                    <measurement group_id="B2" value="40.5" spread="9.14"/>
                    <measurement group_id="B3" value="40.8" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="569"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian / Oriental</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black / African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="414"/>
                    <measurement group_id="B2" value="401"/>
                    <measurement group_id="B3" value="815"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>A treatment-emergent adverse event was defined as any untoward medical occurrence that develops or worsens in severity following start of treatment and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. TEAEs associated with cancer, ischemic heart disease, cerebrovascular events, and arthritis were considered to be of special interest.</description>
        <time_frame>Day 1 up to 7.64 years</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Early Laquinimod</title>
            <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-301 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Switch From Placebo</title>
            <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-301 double-blind study who were administered placebo daily for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>A treatment-emergent adverse event was defined as any untoward medical occurrence that develops or worsens in severity following start of treatment and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. TEAEs associated with cancer, ischemic heart disease, cerebrovascular events, and arthritis were considered to be of special interest.</description>
          <population>Safety analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>=&gt;1 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375"/>
                    <measurement group_id="O2" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;1 Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;1 TEAE of special interest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;1 treatment-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;1 TEAE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;1 Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;1 TEAE causing discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Potentially Clinically Significant Abnormal Vital Signs</title>
        <description>Vital signs with potentially clinically significant abnormal results were evaluated using the following significance criteria:
Pulse rate low: &lt;=45 and decrease &gt;=30 beats/minute
Pulse rate high: &gt;=120 and increase &gt;=30 beats/minute
Systolic blood pressure low: &lt;=90 and decrease &gt;=30 mmHg
Systolic blood pressure high: &gt;=180 and increase &gt;=30 mmHg
Diastolic blood pressure low: &lt;=50 and decrease &gt;=20 mmHg
Diastolic blood pressure high: &gt;=100 and increase &gt;=20 mmHg</description>
        <time_frame>Day 1 up to 7.64 years</time_frame>
        <population>Safety analysis set of participants with a baseline and post-baseline value for that vital sign.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Laquinimod</title>
            <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-301 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Switch From Placebo</title>
            <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-301 double-blind study who were administered placebo daily for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Potentially Clinically Significant Abnormal Vital Signs</title>
          <description>Vital signs with potentially clinically significant abnormal results were evaluated using the following significance criteria:
Pulse rate low: &lt;=45 and decrease &gt;=30 beats/minute
Pulse rate high: &gt;=120 and increase &gt;=30 beats/minute
Systolic blood pressure low: &lt;=90 and decrease &gt;=30 mmHg
Systolic blood pressure high: &gt;=180 and increase &gt;=30 mmHg
Diastolic blood pressure low: &lt;=50 and decrease &gt;=20 mmHg
Diastolic blood pressure high: &gt;=100 and increase &gt;=20 mmHg</description>
          <population>Safety analysis set of participants with a baseline and post-baseline value for that vital sign.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with at least one abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse rate - low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse rate - high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure - low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure - high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure - low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure - high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Serum Chemistry Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study</title>
        <description>Counts include two conditions:
a change from High / Non-PCS at baseline to Low PCS at any point during the study
a change from Low / Non-PCS at baseline to High PCS at any point during the study Participants whose condition was not changed from baseline or was changed to a non- PCS value are included in the population count. ALT=alanine aminotransferase ALP=alkaline phosphatase P-amylase=amylase, pancreatic AST=aspartate aminotransferase CRP=C reactive protein CK=creatine kinase CTN=creatinine FIB=fibrinogen GGT=gamma glutamyl transferase K=potassium</description>
        <time_frame>Day 1 up to 7.64 years</time_frame>
        <population>Safety analysis set of participants with both a baseline and a post-baseline value for the test.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Laquinimod</title>
            <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-301 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Switch From Placebo</title>
            <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-301 double-blind study who were administered placebo daily for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Serum Chemistry Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study</title>
          <description>Counts include two conditions:
a change from High / Non-PCS at baseline to Low PCS at any point during the study
a change from Low / Non-PCS at baseline to High PCS at any point during the study Participants whose condition was not changed from baseline or was changed to a non- PCS value are included in the population count. ALT=alanine aminotransferase ALP=alkaline phosphatase P-amylase=amylase, pancreatic AST=aspartate aminotransferase CRP=C reactive protein CK=creatine kinase CTN=creatinine FIB=fibrinogen GGT=gamma glutamyl transferase K=potassium</description>
          <population>Safety analysis set of participants with both a baseline and a post-baseline value for the test.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="415"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT - change from Low / Non- PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumen - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP - change from Low / Non- PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-Amylase - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST - change from Low / Non- PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP - change from Low / Non- PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK - change from Low / Non- PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTN - change from Low / Non- PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FIB - change from Low / Non- PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT - change from Low / Non- PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate-change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate-change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K - change from High / Non- PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K - change from Low / Non- PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea - change from Low / Non- PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Serum Hematology Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study</title>
        <description>Counts include two conditions:
a change from High / Non-PCS at baseline to Low PCS at any point during the study
a change from Low / Non-PCS at baseline to High PCS at any point during the study Participants whose condition was not changed from baseline or was changed to a non- PCS value are included in the population count.</description>
        <time_frame>Day 1 up to 7.64 years</time_frame>
        <population>Safety analysis set of participants with both a baseline and a post-baseline value for the test.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Laquinimod</title>
            <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-301 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Switch From Placebo</title>
            <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-301 double-blind study who were administered placebo daily for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Serum Hematology Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study</title>
          <description>Counts include two conditions:
a change from High / Non-PCS at baseline to Low PCS at any point during the study
a change from Low / Non-PCS at baseline to High PCS at any point during the study Participants whose condition was not changed from baseline or was changed to a non- PCS value are included in the population count.</description>
          <population>Safety analysis set of participants with both a baseline and a post-baseline value for the test.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="415"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin -change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin -change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils - change from High/Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Electrocardiogram (ECG) Fiindings That Shifted From Baseline to Any Time During the Study</title>
        <description>Shifts are presented as Baseline finding / Worse finding at anytime during the study.
Categories for findings are:
normal
abnormal, not clinically significant (Not CS)
abnormal, clinically significant (CS)</description>
        <time_frame>Day 1 up to 7.64 years</time_frame>
        <population>Safety analysis set of participants with both a baseline and a post-baseline ECG.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Laquinimod</title>
            <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-301 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Switch From Placebo</title>
            <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-301 double-blind study who were administered placebo daily for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Electrocardiogram (ECG) Fiindings That Shifted From Baseline to Any Time During the Study</title>
          <description>Shifts are presented as Baseline finding / Worse finding at anytime during the study.
Categories for findings are:
normal
abnormal, not clinically significant (Not CS)
abnormal, clinically significant (CS)</description>
          <population>Safety analysis set of participants with both a baseline and a post-baseline ECG.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal / Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                    <measurement group_id="O2" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal / Abnormal, Not CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal / Abnormal, CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal, Not CS / Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal, Not CS / Abnormal, Not CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal, Not CS / Abnormal, CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal, CS / Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal, CS / Abnormal, Not CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal, CS / Abnormal, CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 up to 7.64 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Early Laquinimod 0.6 mg</title>
          <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-301 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
        </group>
        <group group_id="E2">
          <title>Switch From Placebo to Laquinimod 0.6 mg</title>
          <description>All participants in MS-LAQ-301E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-301 double-blind study who were administered placebo daily for 24 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Bone marrow oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Parathyroid gland enlargement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Omental infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="423"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hepatic echinococciasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Latent syphilis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Latent tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Mycotoxicosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Ovarian abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Periumbilical abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Intervertebral disc space narrowing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Joint hyperextension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Knee impingement syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Tendon calcification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Breast cancer stage II</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia stage 1</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Langerhans' cell histiocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Oncocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Tubular breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="423"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Simple partial seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agoraphobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Mood disorder due to a general medical condition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Neurosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Ketonuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Urethral meatus stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hydrosalpinx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pharyngeal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Intervertebral disc operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="299" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="300" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="423"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="423"/>
                <counts group_id="E2" events="39" subjects_affected="31" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="31" subjects_affected="24" subjects_at_risk="423"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="423"/>
                <counts group_id="E2" events="37" subjects_affected="26" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="30" subjects_affected="25" subjects_at_risk="423"/>
                <counts group_id="E2" events="38" subjects_affected="31" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="44" subjects_affected="33" subjects_at_risk="423"/>
                <counts group_id="E2" events="46" subjects_affected="33" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="41" subjects_affected="28" subjects_at_risk="423"/>
                <counts group_id="E2" events="46" subjects_affected="34" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="169" subjects_affected="106" subjects_at_risk="423"/>
                <counts group_id="E2" events="210" subjects_affected="112" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="36" subjects_affected="27" subjects_at_risk="423"/>
                <counts group_id="E2" events="47" subjects_affected="28" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="69" subjects_affected="43" subjects_at_risk="423"/>
                <counts group_id="E2" events="65" subjects_affected="41" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="110" subjects_affected="55" subjects_at_risk="423"/>
                <counts group_id="E2" events="76" subjects_affected="39" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="30" subjects_affected="20" subjects_at_risk="423"/>
                <counts group_id="E2" events="30" subjects_affected="23" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="423"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="31" subjects_affected="26" subjects_at_risk="423"/>
                <counts group_id="E2" events="37" subjects_affected="31" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="423"/>
                <counts group_id="E2" events="23" subjects_affected="16" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="57" subjects_affected="41" subjects_at_risk="423"/>
                <counts group_id="E2" events="59" subjects_affected="47" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="127" subjects_affected="78" subjects_at_risk="423"/>
                <counts group_id="E2" events="124" subjects_affected="77" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="423"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="35" subjects_affected="28" subjects_at_risk="423"/>
                <counts group_id="E2" events="45" subjects_affected="33" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="132" subjects_affected="57" subjects_at_risk="423"/>
                <counts group_id="E2" events="160" subjects_affected="86" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" events="35" subjects_affected="17" subjects_at_risk="423"/>
                <counts group_id="E2" events="36" subjects_affected="29" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="41" subjects_affected="35" subjects_at_risk="423"/>
                <counts group_id="E2" events="35" subjects_affected="28" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="423"/>
                <counts group_id="E2" events="40" subjects_affected="35" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="423"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsorâs review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsorâs designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Research</name_or_title>
      <organization>Teva Pharmaceutical Industries, Ltd</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedInfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

